Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
JAZZ Stock Forecast 2025-2026
$108.07
Current Price
$6.67B
Market Cap
Buy 16
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to JAZZ Price Targets
+112.8%
To High Target of $230.00
+64.2%
To Median Target of $177.50
+15.7%
To Low Target of $125.00
JAZZ Price Momentum
-0.8%
1 Week Change
-0.8%
1 Month Change
+1.9%
1 Year Change
-12.2%
Year-to-Date Change
-27.0%
From 52W High of $148.06
+13.2%
From 52W Low of $95.49
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Jazz Pharmaceuticals (JAZZ) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on JAZZ and similar high-potential opportunities.
Latest JAZZ Stock Price Targets & Analyst Predictions
Based on our analysis of 27 Wall Street analysts, JAZZ has a bullish consensus with a median price target of $177.50 (ranging from $125.00 to $230.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $108.07, the median forecast implies a 64.2% upside. This outlook is supported by 16 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Gregory Fraser at Truist Securities, projecting a 112.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
JAZZ Analyst Ratings
16
Buy
2
Hold
0
Sell
JAZZ Price Target Range
Low
$125.00
Average
$177.50
High
$230.00
Current: $108.07
Latest JAZZ Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for JAZZ.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 7, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $166.00 |
| May 7, 2025 | Baird | Joel Beatty | Outperform | Maintains | $155.00 |
| May 7, 2025 | Piper Sandler | David Amsellem | Overweight | Reiterates | $147.00 |
| May 7, 2025 | RBC Capital | Gregory Renza | Outperform | Maintains | $172.00 |
| May 7, 2025 | Needham | Ami Fadia | Buy | Reiterates | $200.00 |
| Apr 10, 2025 | Needham | Ami Fadia | Buy | Reiterates | $210.00 |
| Mar 10, 2025 | HC Wainwright & Co. | Oren Livnat | Buy | Maintains | $217.00 |
| Mar 7, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Assumes | $183.00 |
| Mar 7, 2025 | UBS | Ashwani Verma | Buy | Upgrade | $179.00 |
| Mar 6, 2025 | Truist Securities | Gregory Fraser | Buy | Maintains | $230.00 |
| Mar 5, 2025 | Needham | Ami Fadia | Buy | Reiterates | $210.00 |
| Feb 27, 2025 | Barclays | Balaji Prasad | Overweight | Maintains | $200.00 |
| Feb 26, 2025 | Cantor Fitzgerald | Charles Duncan | Neutral | Downgrade | $150.00 |
| Feb 26, 2025 | RBC Capital | Gregory Renza | Outperform | Maintains | $178.00 |
| Feb 26, 2025 | JP Morgan | Jessica Fye | Overweight | Maintains | $209.00 |
| Feb 26, 2025 | Needham | Ami Fadia | Buy | Maintains | $210.00 |
| Feb 26, 2025 | Piper Sandler | David Amsellem | Overweight | Reiterates | $176.00 |
| Feb 13, 2025 | Wells Fargo | Mohit Bansal | Overweight | Upgrade | $170.00 |
| Dec 12, 2024 | Needham | Ami Fadia | Buy | Reiterates | $207.00 |
| Dec 12, 2024 | Piper Sandler | David Amsellem | Overweight | Reiterates | $163.00 |
Jazz Pharmaceuticals plc (JAZZ) Competitors
The following stocks are similar to Jazz Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
JAZZ
Jazz Pharmaceuticals
mkt cap
6.54B
Jazz Pharmaceuticals plc (JAZZ) Financial Data
Jazz Pharmaceuticals plc has a market capitalization of $6.67B with a P/E ratio of 14.7x. The company generates $4.06B in trailing twelve-month revenue with a 11.9% profit margin.
Revenue growth is -0.5% quarter-over-quarter, while maintaining an operating margin of -2.9% and return on equity of +12.3%.
Valuation Metrics
Market Cap
$6.67B
Enterprise Value
$9.52B
P/E Ratio
14.7x
PEG Ratio
5.0x
Price/Sales
1.6x
Growth & Margins
Revenue Growth (YoY)
-0.5%
Gross Margin
+88.3%
Operating Margin
-2.9%
Net Margin
+11.9%
EPS Growth
-0.5%
Financial Health
Cash/Price Ratio
+38.6%
Current Ratio
3.4x
Debt/Equity
129.8x
ROE
+12.3%
ROA
+4.0%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Jazz Pharmaceuticals plc (JAZZ) Business Model
About Jazz Pharmaceuticals plc
What They Do
Develops life-changing biopharmaceuticals for patients.
Business Model
The company generates revenue by researching, manufacturing, and marketing innovative drugs that address unmet medical needs in various therapeutic areas, including neuroscience, oncology, and sleep medicine. Notable products include Xyrem for narcolepsy and Vyxeos for leukemia, demonstrating its focus on serious health conditions.
Additional Information
Headquartered in Dublin, Ireland, Jazz Pharmaceuticals operates mainly in North America and Europe. The company emphasizes patient care and survival, and leverages strategic collaborations and acquisitions to enhance its product offerings and positively influence the healthcare sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
2,800
CEO
Mr. Bruce C. Cozadd
Country
Ireland
IPO Year
2007
Website
www.jazzpharma.comJazz Pharmaceuticals plc (JAZZ) Latest News & Analysis
Latest News
Quick Summary
Jazz Pharmaceuticals will participate in the Jefferies Global Healthcare Conference on June 5, 2025, with a fireside chat at 6:55 a.m. PDT.
Why It Matters
Jazz Pharmaceuticals' participation in key investor conferences can signal potential growth opportunities and strategic insights, influencing investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Jazz's acquisition of Chimerix diversifies revenue. However, Avadel's appeal allows Lumryz to compete with Xywav. Three oncology catalysts are expected to drive revenue growth by 2026.
Why It Matters
Jazz's Chimerix acquisition diversifies revenue, while Avadel's victory poses a competitive threat. Potential oncology catalysts may drive significant revenue growth by 2026.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Jazz Pharmaceuticals (JAZZ) relies significantly on international revenue, which may impact its financial stability, growth prospects, and stock price performance.
Why It Matters
Jazz's reliance on international revenue can impact its financial stability and growth, affecting overall stock performance amid global market fluctuations and regulatory changes.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Jazz Pharmaceuticals will hold its Q1 2025 Earnings Conference Call on May 6, 2025, at 4:30 PM ET, featuring key executives and analysts from various financial institutions.
Why It Matters
The earnings call will provide insights into Jazz Pharmaceuticals' financial performance and strategic direction, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
17 days ago
Quick Summary
Jazz Pharmaceuticals reported Q1 2025 revenues of $898 million, with Xywav and Epidiolex growing 9% and 10% year-over-year. The company affirmed its 2025 revenue guidance and submitted a sNDA for Zepzelca.
Why It Matters
Strong revenue growth and updated financial guidance signal robust business performance and strategic initiatives, potentially boosting investor confidence and stock value.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Jazz Pharmaceuticals (JAZZ) reported Q3 earnings of $1.68 per share, missing the Zacks Consensus Estimate of $4.51. This is a decline from $2.68 per share in the same quarter last year.
Why It Matters
Jazz Pharmaceuticals' earnings miss signals potential underlying issues, which may lead to reduced investor confidence and a negative impact on the stock price.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About JAZZ Stock
What is Jazz Pharmaceuticals plc's (JAZZ) stock forecast for 2025?
Based on our analysis of 27 Wall Street analysts, Jazz Pharmaceuticals plc (JAZZ) has a median price target of $177.50. The highest price target is $230.00 and the lowest is $125.00.
Is JAZZ stock a good investment in 2025?
According to current analyst ratings, JAZZ has 16 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $108.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for JAZZ stock?
Wall Street analysts predict JAZZ stock could reach $177.50 in the next 12 months. This represents a 64.2% increase from the current price of $108.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Jazz Pharmaceuticals plc's business model?
The company generates revenue by researching, manufacturing, and marketing innovative drugs that address unmet medical needs in various therapeutic areas, including neuroscience, oncology, and sleep medicine. Notable products include Xyrem for narcolepsy and Vyxeos for leukemia, demonstrating its focus on serious health conditions.
What is the highest forecasted price for JAZZ Jazz Pharmaceuticals plc?
The highest price target for JAZZ is $230.00 from Gregory Fraser at Truist Securities, which represents a 112.8% increase from the current price of $108.07.
What is the lowest forecasted price for JAZZ Jazz Pharmaceuticals plc?
The lowest price target for JAZZ is $125.00 from at , which represents a 15.7% increase from the current price of $108.07.
What is the overall JAZZ consensus from analysts for Jazz Pharmaceuticals plc?
The overall analyst consensus for JAZZ is bullish. Out of 27 Wall Street analysts, 16 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $177.50.
How accurate are JAZZ stock price projections?
Stock price projections, including those for Jazz Pharmaceuticals plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 24, 2025 3:22 AM UTC